Seattle Genetics CEO goes inside its lightning-quick Adcetris nod, courtesy of FDA's real-time pilot

Adcetris
Adcetris last month won an approval in newly diagnosed peripheral T-cell lymphoma. (Seattle Genetics)

SAN DIEGO—Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.

“When I read that initially, I was like, ‘my, that is lightspeed,’” he said in an interview at the American Society of Hematology annual meeting. Little did he know that his company would soon put those timelines to shame.

RELATED: Seattle Genetics' Adcetris scores quick lymphoma OK under FDA's new review program

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

It took just 11 days for Seattle Genetics’ Adcetris regimen to snag its approval in patients with newly diagnosed peripheral T-cell lymphoma, with the FDA doling out an OK in the middle of last month. And “for a veteran of decades of working in biotech, I am still pinching myself. Wow,” Siegall said.

It all started when company staffers, who were at the time waiting for data from the phase 3 Echelon-2 study, noticed the RTOR announcement on the FDA website. “We said if our data are really, really good, maybe we should contact FDA and see what this is about,” Siegall recalled.

And after the trial returned numbers that were “very strong,” the company did just that. Regulators made clear that they’d be coming back frequently with questions and comments, and those started rolling in on a daily basis.

“We started getting … ‘can you chart this, can you do this graph, what do you mean by this data, tell us about this data, and what about that,” Siegall said. And on each letter from the FDA gave a short—very short—time to respond, usually 24 hours.

“I think once or twice it said 48 hours. Might have been on a weekend,” Siegall said.

The company worked 24/7—every evening, every weekend—to connect with the FDA. Siegall described the agency as “incredibly engaged.”

“It was just breathtaking to have gone through that, to see what happens and see the FDA with their questions at their finest,” he said. “[Y]ou could just see all the cylinders working along and just moving forward.”

The result? Seattle Genetics submitted its supplemental new drug application for Adcetris in five weeks, which was “an all-time, blistering-fast record for us,” Siegall said, noting that most submissions take about three months. Ultimately, the Adcetris cocktail picked up a go-ahead between six to eight months earlier than the company had expected, helping it get out to more patients.

RELATED: With FDA's new 'real-time' review, Merck's Keytruda scores paramount nod in lung cancer

While multiple drugs have already locked up the FDA’s favor under the new pathway since this summer—Novartis' Kisqali became the first to do so in July, and Merck's Keytruda followed in August—Siegall doesn’t expect to see it happen every time.

“My hunch is this will be reserved for really the best data,” he said.

His advice for companies that do want to go for it? Make sure you have strong enough regulatory and clinical teams “to address the FDA’s questions and comments in an expedient way.”

“It’s not just getting it back quick, it’s getting it back quick and in depth and fully answered with all the relevant data,” he noted.

Suggested Articles

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.